AbbVie (ABBV) and Bristol-Myers Squibb Co. (BMY) announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie's investigational biomarker-specific antibody drug conjugate Rova-T or rovalpituuzumab tesirine, in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a treatment for relapsed extensive-stage small cell lung cancer or SCLC.
from RTT - Biotech http://ift.tt/2apUrGH
via IFTTT
No comments:
Post a Comment